Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CU 105

Next Previous
Drug Profile

CU 105

Alternative Names: CU-105

Latest Information Update: 28 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CURACLE
  • Class Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Cadherin 5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hereditary angioedema

Most Recent Events

  • 28 Jul 2025 No recent reports of development identified for phase-I development in Hereditary-angioedema in USA (PO)
  • 10 Aug 2022 Pharmacodynamics data from a preclinical trial in Hereditary Angioedema(HAE) released by CURACLE (CURACLE pipeline, August 2022)
  • 30 Jun 2022 CURACLE completes a phase I trial in Hereditary angioedema in USA (PO) (CURACLE pipeline, August 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top